head and neck cancer
Conditions
Interventions
Case series:48h after chemotherapy, PEG-rhG-CSF, subcutaneous injection, once per cycle
Sponsors
General Hospital of Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years old; 2. Patients with head and neck cancer diagnosed by histopathology; 3. Patients requiring multi-cycle concurrent chemoradiotherapy; 4. The patient has no serious complications; 5. KPS =70; 6. There were no obvious signs of hematological diseases. Before enrollment, ANC=1.5×10^9/L, platelet count=80×10^9/L, Hb=75g/L, and no bleeding tendency; 7. The patient signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. There are currently uncontrolled infections or systemic antibiotics within 72 hours of receiving chemotherapy; 2. Any abnormal bone marrow hyperplasia and other hematopoietic functions; 3. Patients who have received bone marrow or hematopoietic stem cell transplantation within the past 3 months; 4. Patients with previous malignant tumors that have not been cured, or have brain metastases; 5. TBIL, ALT, AST were >2.5 times the upper limit of normal; if due to liver metastasis, the above indicators >5 times the upper limit of normal; 6. Renal function test: Cr > 1.5 times the upper limit of normal; 7. Anyone who is allergic to this product or other genetically engineered E. coli source; 8. Suffering from mental or systemic diseases, unable to cooperate; 9. Researchers believe that patients who are not suitable for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dynamic Changes of Neutrophil Count Supported by Jin Youli; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of neutropenic fever in each cycle of chemotherapy;Incidence of iii / iv neutropenia in each cycle of chemotherapy supported by JinYouLi;Drug dose adjustment ratio caused by neutropenia in each cycle of chemotherapy;Incidence of delayed chemotherapy caused by neutropenia in each cycle of chemotherapy;Hospitalization rate of patients supported by Jin You Li;antibiotic utilization rate; | — |
Countries
China
Contacts
Public ContactFang Liu
General Hospital of Chinese People's Liberation Army
Outcome results
None listed